Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 2Phase 1/2 1

Status

Unknown 2Terminated 2Completed 1

Sponsor Class

INDUSTRY 5OTHER 4

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 2Genitourinary 2Breast 2Thoracic 1Other hematologic neoplasm 1Gynecologic 1

Conditions

Carcinoma, Renal Cell 2Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Leukemia, B-Cell 1Kidney Neoplasms 1Hodgkin Disease 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Biological Products × Clear all
NCT03549000 2024-12-13

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

Novartis

Phase 1 Terminated
127 enrolled
BreastGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT00014131 2023-10-04

Vaccine Therapy in Treating Patients With Kidney Cancer

Lisata Therapeutics, Inc.

Phase 1 Terminated
9 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04382352 2023-03-24

B002-101

Shanghai Pharmaceuticals Holding Co., Ltd

Phase 1 Completed
23 enrolled
Breast

Breast Neoplasms

NCT03383952 2017-12-27

A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia

Immune Cell, Inc.

Phase 1 Unknown
20 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Lymphoma, B-Cell

NCT03383965 2017-12-27

CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas

Immune Cell, Inc.

Phase 1 Unknown
20 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡